Clinical trials
Clinical Study clinical trials
Below are recruiting clinical study clinical trials, each written for real people, not researchers. We’re tracking 1,809 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06118788RecruitingPhase 1/Phase 2
BG1805 for relapsed or refractory acute myeloid leukemia
This trial tests a new treatment, BG1805, for people with acute myeloid leukemia (AML) that has come back or not responded to standard therapy. It targets a specific marker on leukemia cells called CLL-1.
Guangzhou, GuangdongAges 18–70 - NCT06119256RecruitingPhase 1
TCR-T cells for EBV after stem cell transplant
This trial tests a new treatment using specially trained immune cells (TCR-T cells) to fight Epstein-Barr virus (EBV) infections that can occur after a stem cell transplant for blood cancer. It may help control the virus and prevent complications.
Beijing, Beijing MunicipalityAges 14–75 - NCT06122415Recruiting
Memory clinic study with fluid and cognitive tests
This study looks at people who are being checked for memory or thinking problems. It uses standard tests done at the memory clinic, like a spinal tap and blood draw, plus memory and thinking tests, to learn more about these symptoms. You can join if these tests are already planned as part of your regular care, even if you don't take part in the study.
MalmöAges Any age - NCT06125080RecruitingPhase 2
Study of utidelone plus tirelizumab and bevacizumab for advanced triple-negative breast cancer
This trial is testing a combination of three drugs (utidelone, tirelizumab, and bevacizumab) for people with advanced or metastatic triple-negative breast cancer that has not responded to at least one prior chemotherapy. The goal is to see if this combination can shrink tumors or slow the disease.
Wuhan, HubeiAges 18–70 - NCT06126406RecruitingPhase 1
CEA-targeting CAR-T cell therapy for advanced solid tumors
This trial tests a new immune cell therapy (CAR-T) designed to attack cancer cells that make a protein called CEA. It may be an option for people with advanced colorectal, esophageal, gastric, or pancreatic cancer who have already tried at least two standard treatments.
Wuhu, AnhuiAges 18 years+ - NCT06126510RecruitingPhase 2
Study of VG161 for advanced bone and soft tissue sarcoma
This trial tests a new virus-based therapy (VG161) injected directly into tumors for people with advanced bone and soft tissue sarcoma that hasn't responded to other treatments. The goal is to see if the virus can shrink tumors and slow the cancer's growth.
BeijingAges 18–75 - NCT06128252Recruiting
Taurine with chemotherapy and immunotherapy for gastric cancer
This trial tests whether adding taurine to standard chemo-immunotherapy before surgery helps treat locally advanced gastric cancer. It may be an option for patients whose tumors are PD-L1 positive and can be fully removed with surgery.
Wuhan, HubeiAges 18–75 - NCT06134284RecruitingPhase 4
Ibrutinib plus rituximab for refractory MZL
This trial tests a new combination of two drugs (ibrutinib and rituximab) for people with marginal zone lymphoma that has not responded to other treatments. The goal is to see if this combination can help shrink the lymphoma and improve outcomes.
Hangzhou, ZhejiangAges 18–80 - NCT06135922RecruitingPhase 1
EBV-TCR-T cells for EBV-related HLH or infection
This trial tests a new immune cell therapy (EBV-TCR-T cells) for people with a severe immune reaction caused by the Epstein-Barr virus (EBV-HLH) or active EBV infection. The treatment uses special cells from a matched donor to help your body fight the virus.
Beijing, Beijing MunicipalityAges 1–60 - NCT06136364RecruitingPhase 1
CD7 CAR-T therapy for relapsed T-cell leukemia/lymphoma
This trial tests a new treatment called CD7 CAR-T, which uses your own immune cells modified to find and attack cancer cells that have a protein called CD7 on their surface. It's for people with T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma that has come back or not responded to standard treatments.
ShanghaiAges 18–75 - NCT06139575RecruitingPhase 1/Phase 2
A study of a new drug for advanced prostate cancer
This trial tests a radioactive drug called Lu 177 JH020002 for men with advanced prostate cancer that has spread and stopped responding to hormone therapy. The drug targets a protein on cancer cells to deliver radiation directly, possibly slowing the disease.
Hefei, AnhuiAges 18 years+ - NCT06146231Recruiting
Breast reconstruction with Motiva implants and fat grafting
This study tests a new breast reconstruction method using Motiva Flora implants and your own fat to rebuild the breast after a mastectomy. It is for women who need tissue expansion as part of their reconstruction and have completed cancer treatments at least one year earlier.
GhentAges 18 years+ - NCT06151587RecruitingPhase 3
Eye drop to slow myopia in children
This study tests an eye drop (QLM3004) to see if it can slow down the progression of nearsightedness (myopia) in children. It might be a good option if your child is between 6 and 12, has mild to moderate nearsightedness, and hasn't used other myopia treatments before.
Wenzhou, ZhejiangAges 6–12 - NCT06161870RecruitingPhase 4
Individualized vancomycin dosing for NICU patients
This study tests a personalized dosing approach for the antibiotic vancomycin given to patients in the neurological ICU. It aims to find the right dose for each patient to improve treatment and reduce side effects.
Changsha, HunanAges 18 years+ - NCT06162975Recruiting
Monitoring study for a tick-borne illness
This study is tracking patients with a suspected or confirmed rickettsiosis infection, which is a bacterial disease spread by ticks. It aims to see how the illness progresses and how it is treated.
Chemal, Altai RepublicAges Any age - NCT06163430RecruitingPhase 1/Phase 2
Testing a new pill for CML after other treatments
This study tests a new targeted pill called TERN-701 for people with chronic myeloid leukemia (CML) that has not responded well to or caused side effects from other targeted therapies. The goal is to see if it is safe and effective.
Birmingham, AlabamaAges 18 years+ - NCT06167694RecruitingPhase 1/Phase 2
Study of HRS-8080 and Dalpiciclib for advanced breast cancer
This trial tests a new combination of two drugs (HRS-8080 and Dalpiciclib) for women with advanced breast cancer that cannot be removed by surgery. It may be an option if you have already tried hormone therapy or are starting advanced treatment for the first time.
Beijing, Beijing MunicipalityAges 18–75 - NCT06170489RecruitingPhase 3
Study of JS004 plus toripalimab for Hodgkin lymphoma
This study tests a new combination of two drugs (JS004 plus toripalimab) versus standard chemotherapy for people with Hodgkin lymphoma that no longer responds to PD-1/PD-L1 immunotherapy. The goal is to see if the new combination works better.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06171282RecruitingEarly Phase 1
Virus therapy for advanced bone and soft tissue tumors
This trial tests an investigational virus therapy (R130) injected directly into tumors for people with advanced bone or soft tissue cancer who have exhausted standard treatments or choose not to pursue them.
ShanghaiAges 16–75 - NCT06177925RecruitingPhase 2
Immunotherapy plus chemoradiation for limited spread SCLC
This trial tests a combination of an immunotherapy drug (adebrelimab) plus standard chemotherapy and radiation for people with extensive-stage small cell lung cancer that has only spread to a few places. The goal is to see if this approach can help control the cancer better.
GuangzhouAges 18–75 - NCT06186726RecruitingPhase 2
Carbon ion radiation with chemo for thymic cancer
This trial tests a new type of radiation (carbon ion) plus chemotherapy for thymic tumors that cannot be removed with surgery. It aims to see if this combination can effectively treat the cancer while protecting healthy organs.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06188650Recruiting
New drug combo for advanced lung cancer after two treatments fail
This trial tests a combination of a targeted chemotherapy bead injection into lung arteries, an oral anti-cancer drug, and an immunotherapy for advanced non-small cell lung cancer that has not responded to two prior treatments. It aims to see if this triple approach can help patients who have limited options left.
Ningbo, ZhejiangAges 18 years+ - NCT06190275Recruiting
Immune cell therapy for advanced head and neck cancer
This trial tests a new immune cell therapy (GT201) combined with a PD-1 inhibitor for advanced head and neck cancer. It aims to see if your own immune cells, collected from your tumor, can be boosted to fight the cancer.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06190639RecruitingPhase 2
Sintilimab after surgery for node-positive esophageal cancer
This trial tests whether giving the immunotherapy drug Sintilimab after surgery can help prevent esophageal cancer from coming back. It is for people whose cancer had spread to lymph nodes and who have already had their tumor removed.
Hangzhou, ZhejiangAges 18 years+
Hear when a new Clinical Study trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for clinical study?
- Yes. Clin2 currently lists 1,809 recruiting clinical study studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a clinical study trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a clinical study trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.